Through an integrated approach combining DNA and protein profile of the tumour with heterogeneity detection in the ctDNA, S&G establishes a complete genetic profile of the tumour which can be used to identify response to targeted therapies but also to classical chemotherapies and or novel immunotherapies
OncoSTRAT&GO combines the analysis of a solid biopsy sample (of the primary tumour or of a metastasis) and the analysis of a liquid biopsy (from a blood sample).
The analysis of the solid tumour includes the sequencing of more than 200 genes linked to approved targeted therapies This panel of genes is based on the one used for the NCI-MATCH trial and had been first selected for its scientific relevance: important pathways, signalling cascades, tumour metabolism, apoptosis, growth factors or DNA repair. Nonetheless after the first validation process, we improved the panel to cover some missing regions, add extra genes and compensated some issues with the robustness of some amplicons due to the quality of the DNA. Additionally, we analyse the tumour RNA to detect the presence of fusion transcripts, markers also often linked to treatment resistance or susceptibility to targeted therapies.
Beside the sequencing analysis which has been shown to only reveal partially the identity of the tumour, we perform additional analyses giving critical and non-redundant information using technologies like IHC, phospho-IHC, or looking at microsatellite instability, unusual and damaging splicing mRNA or methylation of genes. Through this unique and integrated approach OncoSTRAT&GO establishes a complete genetic profile of the tumour which can be used to identify response to targeted therapies but also to classical chemotherapies and or novel immunotherapies.
It is essential for metastatic cancer patients to decipher the heterogeneity of the tumour and its related metastases. To answer this question, OncoSTRAT&GO includes the sequencing of 40 genes on the circulating tumour DNA (ctDNA) which isolated in a blood sample from the patient. This blood sample is collected at the same time as the solid biopsy sample or later when the patient orders the test.
This innovative coupled analysis overcomes rebiospy issues and opens doors for personalized monitoring of the disease.
OncoSTRAT&GO is designed to be used in adults with metastatic or non-resectable solid cancers as for which treatment protocols are limited, for patients treated with targeted therapies where hotspots of resistance must be found to access 2nd and 3rd generation of treatments and/or when treatment and attentive response monitoring are highly desirable.
How much does OncoSTRAT&GO cost?
Country-specific price differences
The price indicated here is the recommended retail price. This price might vary in your country, depending on different factors like importation fees, freight costs, currency exchange rate, …
For more info or to order this product in your region, please contact our local representative.
Currently our tests are reimbursed in a growing number of countries. In the United Kingdom, OncoSTRAT&GO is reimbursed for patients insured by BUPA Global Insurance, using code 7331B. Other countries, like Spain, Chili, South Africa or Poland, are also covering totally or partially the cost of our tests. Don’t hesitate to contact us for more information. Click here to read the press release.
Alicia, 49 years old when diagnosed
Was given the OncoDEEP solution following a stage 3 lung cancer.